全部分类
  • Dacarbazine
Dacarbazine的可视化放大

Dacarbazine

A DNA alkylating prodrug

此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

Dacarbazine的二维码
  • 库存: 现货
可选规格
  • 包装
    价格
    促销价
    数量
  • 200mg
    ¥500.00
    400.00
    - +
  • 1g
    ¥950.00
    760.00
    - +
已选 0 0
金额: ¥0.00
首页 收藏
  • 货号: ajci13212
  • CAS: 4342-03-4
  • 别名: 达卡巴嗪; Imidazole Carboxamide
  • 分子式: C6H10N6O
  • 分子量: 182.18
  • 纯度: >98%
  • 溶解度: ≥ 2.3mg/mL in DMSO, ≥ 0.54 mg/mL in Water, <0.49 mg/mL in EtOH
  • 储存: 4°C, protect from light
  • 库存: 现货

Background

Dacarbazine, an antineoplastic chemotherapy drug used in the treatment of various cancers, among them malignant melanoma, Hodgkin lymphoma, sarcoma, and islet cell carcinoma of the pancreas. Dacarbazine is also a member of the class of alkylating agents, which destroy cancer cells by adding an alkyl group (CnH2n+1) to its DNA.[1] The alkyl group is attached to the guanine base of DNA, at the number 7 nitrogen atom of the purine ring.Cancer cells are more sensitive to DNA damage than normal cells, because its proliferate faster and with less error-correcting than healthy cells, but alkylating antineoplastic agent are also toxic to normal cells (cytotoxic), leading to damage, in particular in cells that divide frequently, as those in the gastrointestinal tract, bone marrow, testicles and ovaries.[2]
Dacarbazine is commonly used as a single agent in the treatment of metastatic melanoma in middle of 2006, and as part of the ABVD chemotherapy regimen to treat Hodgkin lymphoma, and in the MAID regimen for sarcoma.Currently, Dacarbazine combined with Oblimersen for the treatment of malignant melanoma in clinical trials.[3]Dacarbazine is normally administered by injection (a shot) or intravenous infusion (IV) under the immediate supervision of a doctor or nurse.Now in phase III about Melanoma Recurrent 2015 March.
参考文献:1. "Alkylating Agents". US National Library of Medicine. Retrieved 2 August 2014.
2. Wiedemann GJ. et al. "Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma". European Journal of Cancer 1996,32A (5): 888–92.
3. MedLine, U.S. National Institutes of Health, National Library of Medicine.
4. CClinicalTrials.gov Identifier:NCT02288897.

没有评价数据

温馨提示 ×
商品已成功加入购物车!
购物车共 0 件商品
去购物车结算